Massachusetts-based Quanterix Corporation announced that it has brought in $46 million in a Series D round of financing. The company is focused on ultrasensitive single molecule testing capabilities.
The reported additional capital, according to a company statement, will be used to develop desk-top instruments, expand the assay menu for protein and nucleic acid biomarkers, bolster the global channel to market and enable new medical studies to be performed with Quanterix’ current technology.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Quanterix’ Simoa platform has already been profiled in 57 peer reviewed publications. The company’s therapeutic areas of focus include neurology, oncology, cardiology, inflammation and infectious disease. Utilizing liquid biopsies and other forms of early detection are integral in Quanterix’ technology designed to help detect disease before symptoms are even present.
ARCH Overage Fund, Cormorant Asset Management and Trinitas Capital led the financing, and existing investors, ARCH Venture Partners, Bain Capital Ventures, Tufts University and Dr. David Walt. Hercules Capital, Inc. also participated.
Photo: Screenshot via Quanterix
